^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | Kanjinti (trastuzumab-anns) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
05/16/2018
Excerpt:
Kanjinti is indicated for the treatment of...in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab....Kanjinti should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.
Secondary therapy:
Aromatase inhibitor
Source:
Published date:
05/16/2018
Excerpt:
Kanjinti is indicated for the treatment of...Hormone-receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments….Kanjinti should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.
